Fesarius Therapeutics
Summary active Updated Jun 13, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Fesarius Therapeutics is a New York-based commercial-stage medical technology company focused on dermal repair 12. Its flagship product, DermiSphere, is the first hydrogel Dermal Regeneration Template (hDRT) cleared by the FDA, with 2025 clearance for the management of multiple wound types 12. On June 10, 2026, the company announced the closing of an oversubscribed $20 million Series A led by Jefferson Life Sciences, with participation from Johnson & Johnson Innovation – JJDC, Empire State Development’s NY Ventures, and the American Society of Plastic Surgeons (ASPS) 123. The capital will support commercial expansion of DermiSphere, pursuit of Breakthrough Device Designation, and advancement of clinical studies for its OneStep procedure 13.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-10 | Series A | $20M | Jefferson Life Sciences | Johnson & Johnson Innovation – JJDC, NY Ventures, American Society of Plastic Surgeons 123 |
What Investors Say
“DermiSphere is already making a difference for patients. We believe Fesarius is positioned to redefine the category.”
— Laura Lande-Diner, Jefferson Life Sciences 2
“This inaugural investment marks a new chapter for ASPS Ventures, one where we move from advocates to active partners.”
— Michael Costelloe, American Society of Plastic Surgeons 2
What Founders Say
“Patients are experiencing promising outcomes already and this financing accelerates our clinical programs and expands our commercial reach.”
— Tom Roueche, President & CEO, Fesarius Therapeutics 2
Sources
-
Pulse 2.0, “Fesarius Therapeutics Raises $20 Million Series A To Advance Dermal Repair Technology,” June 10, 2026. Accessed June 2026. https://pulse2.com/fesarius-therapeutics-raises-20-million-series-a-to-advance-dermal-repair-technology/↩↩↩↩↩
-
BioSpace, “FesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic Surgeons,” June 10, 2026. Accessed June 2026. https://www.biospace.com/press-releases/fesariustherapeutics-closes-oversubscribed-20m-series-a-led-by-jefferson-life-sciences-and-backed-by-ny-ventures-and-the-american-society-of-plastic-surgeons↩↩↩↩↩↩↩
-
citybiz, “Fesarius Therapeutics Raises $20 Million Series A to Expand Commercial Adoption of DermiSphere,” June 10, 2026. Accessed June 2026. https://www.citybiz.co/article/858497/fesarius-therapeutics-raises-20-million-series-a-to-expand-commercial-adoption-of-dermisphere/↩↩↩